Construction and Preliminary Application of COM-B Based Sedentary Behavioural Booster Intervention Programme for Elderly Stroke Patients

June 1, 2024 updated by: Liu Shuxian
Explore the application effect of the sedentary behaviour intervention program for elderly stroke patients based on the COM-B model.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The goal of this clinical trial is to text about in the application effect of the sedentary behaviour intervention program for elderly stroke patients based on the COM-B model. The main question it aims to answer are:

  • Changes in sedentary behaviour in elderly stroke patients Participants will received a 12-week sedentary behaviour intervention programme.

Researchers will compare differences in sedentary behaviour between routine care control and intervention groups.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Meet the diagnostic criteria for cerebral infarction and cerebral hemorrhage in the Diagnostic Points for Various Major Cerebrovascular Diseases in China 2019 issued by the Cerebrovascular Disease Group of the Neurology Branch of the Chinese Medical Association;
  • Age ≥60 years;
  • National Institute of Health stroke scale (NIHSS) score <5 (i.e., mild stroke), stable vital signs, and able to cooperate with the survey;
  • Total sedentary time ≥6 hours/day measured using the International Physical Activity Questionnaire;
  • Resident for ≥6 months in the community residents;
  • Patients or under the guidance of others can use WeChat.

Exclusion Criteria:

  • Functional ambulation category scale (FAC) score <2;
  • serious myocardial infarction, cerebral hemorrhage and pulmonary embolism in the acute stage of the need to limit the activities of the situation;
  • is participating in other physical activity or sedentary behavioral intervention programs;
  • severe muscle weakness, fractures and other diseases resulting in limited physical activity;
  • serious mental disorders such as schizophrenia or dementia resulting in severe cognitive impairment;
  • speech and communication disorders.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: intervention group
Knowledge (information support, changing health attitudes); Motivation (motivation to change sedentary behaviour and improve exercise compliance); Capacity (development of exercise plans to improve sedentary behaviour change); Opportunities (increasing the timing of exercise and creating opportunities for sedentary behaviour change); Behaviour (monitoring and reinforcing sedentary behaviour change)
Other: Sedentary behaviour intervention
COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
No Intervention: control group
Routine nursing education

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
sedentary time
Time Frame: baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
International Physical Activity Questionnaire (IPAQ) Sedentary behavior and physical activity levels were assessed using the International Physical Activity Questionnaire (IPAQ), which was developed by the International Physical Activity Measurement Working Group (IPAMWG) in 2001, with the coefficients for sedentary behavior and validity scale correlation coefficients of 0.887 and 0.760 for sedentary behavior and 0.779 and 0.718 for physical activity, respectively. In this questionnaire, the metabolic equivalent of walking was 3.3, moderate activity intensity was 4.0, and high intensity activity was 8.0. The formula for calculating sedentary time was: sedentary time per day = (weekday sitting time x 5 + weekend sitting time x 2)/7
baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Social Support
Time Frame: baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Social Support Rating Scale (SSRS) This scale is mainly used for the evaluation of individual social support status, with 10 entries, including 3 dimensions of subjective support, objective support and utilization of support. The scoring method is the sum of the scores of each entry, and the higher the score, the higher the level of social support. The scale reliability coefficient was 0.896.
baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Depression
Time Frame: baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
The Self-Rating Depression Scale (SDS) Self-Rating Depression Scale (SDS) is a 20-item self-rating scale, with scores of 1, 2, 3, and 4 for each item, and the sum of the scores of all items ranging from 53-62 indicating mild depression; 63-72 indicating moderate depression; and more than 72 indicating severe depression. The higher the total score, the more severe the depression. The Cronbach's alpha coefficient of the scale was 0.920.
baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Exercise Adherence
Time Frame: baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Functional Exercise Adherence Scale for Stroke Patients (Questionnaire of Exercise Adherence, EAQ) The EAQ was developed by Beilei Lin in 2013 to assess patients' adherence to rehabilitation exercises. It contains 14 entries divided into 3 dimensions (physical participation in exercise, exercise effect monitoring and active seeking of exercise advice adherence), with each entry scored on a scale of 1 to 4. The total score of the scale ranges from 14 to 56, and the adherence index is the percentage value of the patient's measured score to the maximum score of the scale (56). The level of patient adherence was judged according to the adherence index: ≤50% = low level, 50% to 75% = medium level, and ≥75% = high level. The scale had good content validity (0.95), structural validity and validity scale validity, and high retest reliability (ICC: 0.778-0.850) and internal consistency (Cronbach's alpha coefficient: 0.923).
baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Ability to perform activities of daily living
Time Frame: baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
Modified Barthel Index Scale (MBI) The MBI scale was made in 1989 by Canadian scholars Shah and Vanchay, who subdivided the BI scale into 5 levels.The MBI scale[117] contains 10 basic activities of daily living (ADLs) such as dressing, grooming, eating, bathing, walking, transferring from bed and chair to toilet, etc., and is divided into 5 levels according to the degree of independence from 1-5, with the lowest being 1 and the highest being 5, which is determined and scored out of 100 points according to the completion of the patient's performance. The higher the score, the better the ability to perform activities of daily living.
baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
10 meter maximum walking speed
Time Frame: baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).
10 meter maximum walking speed (10 mMWS) The 10m maximum walking speed can reflect the patient's walking speed and walking functional status. First, a 16-meter straight line is drawn on a smooth surface, with markings at 3 and 13 meters. Let the patient walk along this straight line, assistive devices can be used, the timing starts when they reach 3 meters and ends at 13 meters, the time needed is recorded and the step speed is calculated at the same time, in this study, the test was done 3 times and the average value was taken, the faster the speed represents the better the walking ability and the slower the worse.
baseline (T0), 12-week post-intervention (T1), and 8-week follow-up (T2).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Liu Shuxian

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Harbin Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 1, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 6, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 6, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HMUDQ20231116221

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Sedentary behaviour intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings